Moxifloxacine Eg (Moxifloxacin)

Moxifloxacin is indicated for several bacterial infections affecting the respiratory tract, skin and intra‑abdominal sites.

• Community‑acquired bacterial pneumonia: effective eradication of the causative pathogens and improvement of pulmonary function.
• Acute bacterial sinusitis: rapid reduction of sinus inflammation and bacterial load.
• Acute bacterial exacerbation of chronic bronchitis: relief of symptoms and prevention of disease progression.
• Skin and skin structure infections: clearance of skin‑associated bacterial pathogens.
• Intra‑abdominal infections: control of mixed‑organism infections within the abdominal cavity.

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. By stabilizing the enzyme–DNA complex, it prevents the resealing of DNA strands, leading to bacterial cell death. This dual‑target action provides broad‑spectrum activity against Gram‑positive, Gram‑negative and atypical organisms.

Moxifloxacine Eg may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhea: loose stools, occasionally watery.
• Headache: transient cranial discomfort.
• Rash: mild skin erythema or itching.

Serious or Rare Side Effects

• Tendon rupture: sudden pain and loss of function, especially in the Achilles tendon.
• QT interval prolongation: risk of cardiac arrhythmias.
• Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome.
• Clostridioides difficile colitis: severe diarrhea due to intestinal flora disruption.
• Hepatic toxicity: elevated liver enzymes or jaundice.

Before prescribing Moxifloxacine Eg, clinicians should consider several safety factors.

• Renal impairment: adjust therapy based on renal function and monitor for accumulation.
• History of tendon disorders: avoid use or monitor closely for tendon pain or swelling.
• Cardiac arrhythmias: caution in patients with known QT prolongation or electrolyte disturbances.
• Pregnancy: Category C; use only if potential benefits justify potential fetal risk.
• Concomitant antacids or mineral supplements: separate administration by at least two hours to ensure absorption.
• Store at ambient temperature: keep in the original container, protect from moisture and light.

Moxifloxacine Eg can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Systemic corticosteroids: increased risk of tendon rupture.
• Other QT‑prolonging agents (e.g., macrolides, antiarrhythmics): heightened arrhythmia risk.
• CYP1A2 inhibitors (e.g., fluvoxamine): may raise plasma concentrations of moxifloxacin.

Moderate Interactions (Monitor Closely)

• Antacids or supplements containing aluminum, magnesium, calcium, or iron: may reduce oral absorption.
• Warfarin: potential enhancement of anticoagulant effect, requiring INR monitoring.
• Theophylline: possible increase in serum theophylline levels, necessitating dosage adjustment.